By Sabela Ojea

Seagen said Tuesday its shareholders voted in favor of Pfizer buying the company for $43 billion.

The biotechnology cancer specialist continues to expect to close the deal in late 2023 or early 2024 amid pending regulatory approvals.

In March, Pfizer said it entered into a definitive merger agreement with Seagen for $299 per share in cash to invest in cancer treatments.

The boards of directors of both parties back the transaction.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

May 30, 2023 16:00 ET (20:00 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 8 2023 まで 9 2023 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 9 2022 まで 9 2023 Pfizerのチャートをもっと見るにはこちらをクリック